- Home
- JAGX vs MYNZ Comparison
JAGX vs MYNZ Comparison
Compare JAGX & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAGX | MYNZ |
|---|---|---|
| Founded | 2013 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 5.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | JAGX | MYNZ |
|---|---|---|
| Price | $1.18 | $1.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $60.00 | $14.00 |
| AVG Volume (30 Days) | ★ 380.3K | 305.7K |
| Earning Date | 11-17-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,785,000.00 | $659,935.00 |
| Revenue This Year | $22.41 | N/A |
| Revenue Next Year | $30.00 | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.45 | N/A |
| 52 Week Low | $1.00 | $0.92 |
| 52 Week High | $33.25 | $8.20 |
Technical Indicators
Market Signals| Indicator | JAGX | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 40.78 | 36.55 |
| Support Level | $1.05 | $1.00 |
| Resistance Level | $1.36 | $1.15 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 34.00 | 33.33 |
Price Performance
Historical ComparisonAbout JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.